Navigation Links
Mylan Declares Quarterly Preferred Stock Dividend
Date:1/30/2008

PITTSBURGH, Jan. 30 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL) today announced that in accordance with its 2.139 million preferred stock issuance, the Company has declared an initial quarterly dividend of $15.53 per share (based on the annual dividend rate of 6.5% and a liquidation preference of $1,000.00 per share and the time period from the date of issuance to February 15, 2008) payable on February 15, 2008 to holders of preferred stock of record as of February 1, 2008.

Mylan Inc. is one of the world's leading quality generic and specialty pharmaceutical companies. The Company offers one of the industry's broadest and highest quality product portfolios, a robust product pipeline and a global commercial footprint through operations in more than 90 countries. Through its controlling interest in Matrix Laboratories Limited, Mylan has direct access to one of the largest active pharmaceutical ingredient (API) manufacturers in the world. Dey L.P., Mylan's fully integrated specialty business, provides the Company with innovative and diversified opportunities in the respiratory and allergy therapeutic areas.


'/>"/>
SOURCE Mylan Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Mylan Provides Update Relating to Ongoing Lorazepam and Clorazepate Litigation
2. Mylan Announces Final FDA Approval for Cetirizine Hydrochloride Tablets
3. Mylan Sets Date of 2008 Annual Meeting
4. Mylan Receives $26.2 Million From Exercise of Overallotment Option of Common Stock
5. Mylan Announces Tentative FDA Approval Under PEPFAR for Tenofovir Disoproxil Fumarate Tablets
6. Mylan Completes $2.89 Billion of Equity Financings, Including Exercise of Overallotment Option of Mandatory Convertible Preferred Stock
7. Mylan Prices Offerings of Common Stock and Mandatory Convertible Preferred Stock
8. Mylan Announces Appointment of Joseph F. Haggerty as Senior Vice President and Global General Counsel
9. Mylan Announces Settlement of Paroxetine Hydrochloride Extended-Release Tablets with GlaxoSmithKline
10. Mylan Settles Its First-to-File Opportunity on Levetiracetam with UCB
11. Mylan Vice Chairman and CEO Robert J. Coury to Ring NYSE Closing Bell(R) in Celebration of Merck Generics Acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 29, 2017 , ... ... is growing as it continues developing an ANSI-approved, consensus-based American National Standard ... which plans to publish the first ANSI-approved GMP standard for dietary supplements ...
(Date:3/29/2017)... , ... March 29, 2017 , ... HealthCareMandA.com will host ... April 20, 2017, at 1:00 PM ET. A recording of the webinar will also ... Webinar Series. , Home health and hospice companies are still popular targets for healthcare ...
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... ... of Gastrointestinal Oncology™ (SOGO™), a specialized continuing medical education conference for clinicians who ... at Intercontinental Time Square, New York. , The program will be led ...
(Date:3/28/2017)... CA (PRWEB) , ... March 28, 2017 , ... Tuesday, ... asking the American public to take the Diabetes Risk Test to find out if ... the Los Angeles World Airports will light up the evening sky by programming the ...
(Date:3/28/2017)... ... March 28, 2017 , ... Revolution for Truth has organized ... protect parental rights and civil liberties, and to restore transparency within government agencies ... coincides with a press conference taking place Friday morning calling on President Trump ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... , March 29, 2017 /PRNewswire/ - Medicure Inc. ("Medicure") ... financial results for the year ended December 31, ... 2017. The results are being released later than ... statements will include the operations and balances of ... 2016.  This release and filing date meets TSX ...
(Date:3/28/2017)... "Chemotherapy Induced Neutropenia (CIN) – Market Insights, Epidemiology and ... market trends of the Chemotherapy Induced Neutropenia for the seven major ... ( France , Germany ... UK) and Japan , as well as rest ... world (RoW). The Report covers the therapeutics market revenue, ...
(Date:3/28/2017)... , March 28, 2017  "US Cancer ... on the various indicators and trend analysis related ... drugs in mainstream pharmaceutical market in US. The ... for the growth on cancer generics drugs in ... in saving of billions of dollars for various ...
Breaking Medicine Technology: